Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan versus standard of care in active ANCA-associated vasculitis
NL-OMON60255Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) comparing Iptacopan arm with Standard of care arm (2 arms). Primary endpoint: Sustained remission through Week 48. Started Nov 2024; status: completed.
02
Drugs
Iptacopan
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NL-OMON60255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60255.